Bristol Myers to sell 60% stake in China joint venture
NeutralFinancial Markets

Bristol Myers Squibb has announced its decision to sell a 60% stake in its joint venture in China. This move is significant as it reflects the company's strategic shift in focus and aims to streamline its operations in the region. The sale could potentially open new opportunities for growth and partnerships in the Chinese market, which is crucial for pharmaceutical companies looking to expand their global footprint.
— Curated by the World Pulse Now AI Editorial System